Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Desensitization and Tachyphylaxis01:20

Desensitization and Tachyphylaxis

2.3K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
2.3K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

270
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
270
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

152
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
152
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

340
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
340
Pulmonary Embolism III: Nursing Management01:27

Pulmonary Embolism III: Nursing Management

52
A pulmonary embolism occurs when a thrombus, amniotic fluid, tumor tissue, fat, or air embolus blocks one or more pulmonary arteries. Effective nursing management and patient education are crucial for improving outcomes and preventing recurrence.Nursing management starts with obtaining a comprehensive patient history, particularly noting any history of deep vein thrombosis (DVT). Assess for clinical manifestations, including dyspnea, chest pain, crackles, heart murmurs, and signs of right-sided...
52
Hemodialysis III: Nursing Management01:25

Hemodialysis III: Nursing Management

226
The nursing management of a patient undergoing hemodialysis includes several critical steps, starting with a thorough assessment before the procedure.Before the Hemodialysis ProcedureFirst, record the patient's vital signs—blood pressure, heart rate, respiratory rate, and temperature—to establish a baseline. This baseline is essential for detecting conditions such as hypotension that could impact the patient's response to dialysis. Document the patient's pre-dialysis weight, as this...
226

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

At-home, self-sampling of the skin microbiome: development of an unsupervised sampling approach.

Access microbiology·2025
Same author

Friedreich's ataxia: A case series, literature review, and recommendations for pregnancy.

International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics·2025
Same author

Physical injury in men after sexual assault: An analysis of 137 cases.

Forensic science international·2024
Same author

Inpatient referrals to a specialist falls and syncope service: prevalence of STOPPFall FRIDs and review of deprescribing patterns.

European journal of clinical pharmacology·2024
Same author

Women attending the sexual assault treatment unit services in the Republic of Ireland: A 7-year review.

International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics·2024
Same author

Delayed and significant hypercalcaemia due to teriparatide therapy: a case report and review.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2024
Same journal

Unlocking the potential of electronic health records for research purposes.

Irish medical journal·2026
Same journal

ICU Handover: A Persistent Vulnerability in Critical Care Settings.

Irish medical journal·2026
Same journal

The Sugar-Sweetened Beverage Tax (Sugar Tax): Innovation and Stasis.

Irish medical journal·2026
Same journal

Gastrointestinal trichobezoars presenting as abdominal pain and obstruction - Rapunzel syndrome.

Irish medical journal·2026
Same journal

When Sepsis Kills: A Fatal Cascade of Invasive Group A Streptococcal Sepsis.

Irish medical journal·2026
Same journal

Fulminant Thrombotic Thrombocytopenic Purpura presenting through the FAST Stroke Pathway.

Irish medical journal·2026
See all related articles

Related Experiment Video

Updated: Sep 24, 2025

Author Spotlight: Integrating Traditional Chinese Medicine with Modern Pharmacology and Genomics for Assessing Postmenopausal Osteoporosis in Mice
07:20

Author Spotlight: Integrating Traditional Chinese Medicine with Modern Pharmacology and Genomics for Assessing Postmenopausal Osteoporosis in Mice

Published on: August 23, 2024

673

Treatment Challenges When Stopping Denosumab.

A McDonough1, K Malomo1, F Brennan1

  • 1Bone Health and Osteoporosis Unit, Mercer's Institute for Successful Ageing, St. James's Hospital.

Irish Medical Journal
|May 9, 2022
PubMed
Summary
This summary is machine-generated.

Stopping denosumab treatment for osteoporosis can lead to rapid bone loss and fracture risk. Transitioning to bisphosphonates may not prevent this rebound bone loss, highlighting the need for careful monitoring.

More Related Videos

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
04:37

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

Published on: June 6, 2025

344
Drug Treatment and In Vivo Imaging of Osteoblast-Osteoclast Interactions in a Medaka Fish Osteoporosis Model
08:53

Drug Treatment and In Vivo Imaging of Osteoblast-Osteoclast Interactions in a Medaka Fish Osteoporosis Model

Published on: January 1, 2017

9.3K

Related Experiment Videos

Last Updated: Sep 24, 2025

Author Spotlight: Integrating Traditional Chinese Medicine with Modern Pharmacology and Genomics for Assessing Postmenopausal Osteoporosis in Mice
07:20

Author Spotlight: Integrating Traditional Chinese Medicine with Modern Pharmacology and Genomics for Assessing Postmenopausal Osteoporosis in Mice

Published on: August 23, 2024

673
Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
04:37

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

Published on: June 6, 2025

344
Drug Treatment and In Vivo Imaging of Osteoblast-Osteoclast Interactions in a Medaka Fish Osteoporosis Model
08:53

Drug Treatment and In Vivo Imaging of Osteoblast-Osteoclast Interactions in a Medaka Fish Osteoporosis Model

Published on: January 1, 2017

9.3K

Area of Science:

  • Endocrinology
  • Bone Metabolism
  • Pharmacology

Background:

  • Denosumab is a widely used treatment for osteoporosis.
  • Discontinuation of denosumab is associated with rebound bone loss and increased fracture risk.
  • Clinical decisions regarding the optimal management after denosumab cessation are challenging.

Observation:

  • A case series of eight patients (aged 56-89) demonstrated rebound bone loss and increased bone turnover markers (BTM) after stopping denosumab.
  • Transitions to oral bisphosphonates or standard zoledronic acid were insufficient to prevent bone mineral density (BMD) decline in several patients.
  • One patient with prior long-term bisphosphonate use maintained stable BMD after denosumab cessation without further therapy.

Findings:

  • Drug holidays following denosumab treatment are not advisable due to the risk of significant bone loss.
  • The duration of denosumab treatment may influence the severity of rebound bone loss.
  • Prior use of bisphosphonates might mitigate the risk of bone loss upon denosumab discontinuation.
  • Standard zoledronic acid doses may not be adequate to prevent bone loss in all patients post-denosumab.
  • Bone turnover markers (BTM) can aid in monitoring treatment effectiveness and guiding subsequent therapeutic decisions.

Implications:

  • Careful consideration and monitoring are essential when discontinuing denosumab.
  • Alternative or intensified treatment strategies may be required to manage bone loss after denosumab cessation.
  • Bone turnover markers (BTM) may play a crucial role in personalized osteoporosis management following denosumab therapy.
  • Further research is needed to establish optimal transition strategies and long-term management protocols after denosumab discontinuation.